VANCOUVER, BC, Sept. 16, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of digital therapies.

The company will work with the Digital Therapeutics Alliance focusing on value and reimbursement, policy and regulation, and awareness to educate the broader health care industry about the benefits of including new technologies in current treatment regimes. This framework will shape the way that the myriad of new technologies currently being developed are ultimately adopted and utilized, as well as help clinicians, caregivers, and consumers wade through a flood of options hitting the market.

"Joining the Digital Therapeutics Alliance is a huge opportunity for our company to be at the forefront of how digital technology is adopted and regulated in the mental health industry," said Kelsey Ramsden, President and CEO of MINDCURE. "We look forward to collaborating with leaders in the space to help define the future as we invest in and research the potential of digital therapeutics, with a focus on psychedelics."

"We are excited to welcome MINDCURE to the DTA community to help drive advancements in the DTx industry," said Andy Molnar, CEO of the Digital Therapeutics Alliance. "As our first member headquartered in Canada, their addition expands our global footprint as well as strengthens our coalition of digital therapeutics manufacturers focused on enabling expanded access to safe and effective DTx products to improve mental health care."

MINDCURE is positioning its software application, iSTRYM, as the industry's distribution network for science-based, evidence-backed protocols and artificial intelligence data systems. iSTRYM provides data-driven support as it optimizes the healing journey for patients and clinicians — before, during, and after therapy sessions. iSTRYM is built to shift the paradigm of care and access for psychedelic-assisted psychotherapy; reducing the cost of care, improving patient outcomes, and providing a distribution network for psychedelic companies to distribute protocols.

"Digital therapeutics is the future of mental health care, and there's a need to balance the fast adoption of new technologies with thoughtful regulation," said Ramsden. "This partnership solidifies an industry leadership role for the company as we continue to execute on our strategic research and development goals."

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

About Digital Therapeutics Alliance
Founded in 2017, the Digital Therapeutics Alliance is a 501(c)(6) non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics. As the leading international organization on digital therapeutic thought leadership and education, the Digital Therapeutics Alliance provides patients, clinicians, payors, and policymakers with the necessary tools to evaluate and utilize DTx products.

Forward-Looking Information
Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE's business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE's business; there will be a demand for MINDCURE's products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that iSTRYM will be developed, optimized and operate as contemplated within the psychedelics industry; that the Company will be effective in obtaining the patents applied for synthesizing ibogaine, or synthesizing ibogaine, or developing synthesized ibogaine for research, medical or commercial use; that MINDCURE will advance wellness worldwide; that iSTRYM will be brought to commercial deployment in the near term or otherwise or that it will reduce symptoms, improve quality of life, or support transformation and healing, or that the deployment may not occur at the scale or within the timeframe contemplated.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed. 

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindcure-joins-digital-therapeutics-alliance-to-drive-innovation-in-the-mental-health-industry-301378330.html

SOURCE Mind Cure Health Inc.